celecoxib has been researched along with sphingosine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cocco, G | 1 |
| Huwiler, A; Koch, A; Meyer Zu Heringdorf, D; Pfeilschifter, J; Völzke, A | 1 |
2 other study(ies) available for celecoxib and sphingosine
| Article | Year |
|---|---|
A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart?
Topics: Arthritis, Psoriatic; Atrial Fibrillation; Autoimmune Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Factor V; Fingolimod Hydrochloride; Heart; Heart Diseases; Heart Failure; Humans; Hypertension; Immunosuppressive Agents; Male; Middle Aged; Mitral Valve Insufficiency; Multiple Sclerosis; Mutation; Myocardium; Propylene Glycols; Pyrazoles; Sjogren's Syndrome; Sphingosine; Sulfonamides | 2012 |
Sphingosine 1-phosphate (S1P) induces COX-2 expression and PGE2 formation via S1P receptor 2 in renal mesangial cells.
Topics: Angiotensin II; Animals; Celecoxib; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Gene Expression Regulation, Enzymologic; Humans; Interleukin-1beta; Lysophospholipids; Male; MAP Kinase Signaling System; Mesangial Cells; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; Sulfonamides; Up-Regulation; Vasoconstrictor Agents | 2014 |